Roivant Sci­ences in ex­clu­sive joint ven­ture talks with Ar­bu­tus; DBV gets green light to sub­mit peanut al­ler­gy patch

→ Months af­ter in­vest­ing $116 mil­lion in­to Cana­da’s Ar­bu­tus $ABUS, Roivant Sci­ences con­firmed ear­ly spec­u­la­tions that it’s ex­plor­ing a joint ven­ture deal. The com­pa­nies spread word Wednes­day that they have en­tered in­to a month­long pe­ri­od of ex­clu­sive ne­go­ti­a­tions to joint­ly de­vel­op Ar­bu­tus’ nu­cle­ic acid de­liv­ery plat­form through a new com­pa­ny. Ar­bu­tus has built a rep for it­self with both its in-house he­pati­tis B ther­a­py and drugs from oth­er com­pa­nies, such as Al­ny­lam’s patisir­an, that uti­lize its de­liv­ery tech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.